Our subsidiary 4Moving Biotech, was presented at OARSI- World Congress on Osteoarthritis. It was an excellent opportunity to share our subsidiary’s latest progress and development.

Our subsidiary Co-founder/CMO Pr. Francis Berenbaum showcased two posters during the OARSI congress.

First poster at OA clinical trial symposium on March 16, 2023

Poster title: GLP1 analogues as a potential DMOAD: why, how, when?

The second Poster was a keynote presented during the OA research plenary session on March 17, 2023.

Poster title: Have We Been Driving in the Wrong Lane? Pivoting from Past Setbacks to Future Therapeutic Successes